Bone morphogenetic protein-2 (BMP-2), a glycosylated protein, has been demonstrated to play a key role in osteoblast differentiation. However, the function of its glycosylation is incompletely understood. In this study, we examined the role that N-linked glycans (NLG) play in the secretion of BMP-2. Blocking the addition of NLGs or inhibiting initial glycan processing prevented the secretion of BMP-2. To identify the specific glycosylation sites, we abolished potential sites of N-linked glycosylation (Asn-Xaa-Ser/Thr) in BMP-2 by mutating the Asn residues to Gln individually or in combination, expressed the BMP-2 mutants in Chinese hamster ovary (CHO) and human embryonic kidney 293T (HEK293T) cells and determined their glycosylation state by using peptide:N-glycosidase F and endoglycosidase H digestion. We found that human BMP-2 contains three NLG on N135, N200 and N338. Elimination of N-glycosylation by mutation of N135 (N135Q) abolished the BMP-2 secretion from CHO cells. Overexpression of the BMP-2 mutant N135Q elicited endoplasmic reticulum (ER) stress and retention within the ER in CHO cells, indicating that N-glycosylation is required for folding of human BMP-2. Furthermore, we demonstrated that glycosylation at N135 was necessary for BMP-2-induced osteoblast differentiation in MC3T3-E1 cells. Taken together, these data provide further evidence of the critical role that individual NLG may play an important role in determining BMP-2 folding, secretion and function.
Introduction
Osteoblast differentiation is tightly regulated by a range of hormones, cytokines and multiple transcription factors (Yamaguchi et al. 2000; Komori 2006 ). Bone morphogenetic protein-2 (BMP-2), which is a member of the BMP subgroup of the transforming growth factor-β (TGF-β) superfamily (Wozney et al. 1988) , was demonstrated to play a crucial role in inducing osteoblastic differentiation of mesenchymal cells in vitro and enhances osteoblastic function (Zhao et al. 2002; Canalis et al. 2003) . Several lines of evidence suggest that BMP-2 treatment regulates the expression of several osteoblastic genes, including alkaline phosphatase (ALP) and osteocalcin (OC; Takuwa et al. 1991; Sakano et al. 1993; Ducy and Karsenty 1995; Chen et al. 1997; Ducy et al. 1999; Javed et al. 2001; Saito et al. 2011) and induces the osteogenic trans-differentiation of fibrogenic, myogenic and adipogenic cells both in vitro and in vivo (Katagiri et al. 1990 (Katagiri et al. , 1994 .
As with all TGF-β family members, human BMP-2 is initially synthesized as a large inactive precursor ( pre-pro-BMP-2), a 396 amino acid (aa) preproprotein, which contains a 23-aa signal sequence, a 259-aa prosegment and a 114-aa mature region (Wozney et al. 1988) . The pre-pro-BMP-2 is proteolytically cleaved to generate the active C-terminal ligand (Wozney et al. 1988) . Once cleaved, the mature active BMP-2, an 18-kDa glycosylated peptide, is secreted from the cell and forms a disulfide linked homodimers and heterodimers with BMP-7 through the highly conserved seven cystine residues (Wozney et al. 1988; Wang et al. 1990; Sun and Davies 1995; Chen et al. 2004) . It has been shown that BMP-2 is a glycoprotein, and BMP-2 purified from Chinese hamster ovary (CHO) culture medium has been shown to be N-glycosylated (Wozney et al. 1988; Israel et al. 1992) , which indicates that BMP-2 undergoes N-glycosylation during its synthesis. However, the functional role of N-glycosylation of BMP-2 remains to be determined. N-glycosylation of proteins is one of the most abundant post-translational modifications, nearly one-half of all known proteins in eukaryotes are glycosylated and more over half of the glycosylated proteins are reported to have N-linked oligosaccharides (Helenius and Aebi 2001) . It is characterized by the addition of a carbohydrate moiety to the nascent glycoproteins via a β-glycosidic linkage between an N-acetylglucosamine residue and the δ-amide of an asparagine residue in the sequence Asn-Xaa-Ser/Thr (where Xaa represents any amino acid except proline; Gavel and von Heijne 1990; Miletich and Broze 1990) .The N-linked glycosylation, an enzymatic process which takes place inside the lumen of the endoplasmic reticulum (ER) and the Golgi apparatus (Rek et al. 2009 ), could facilitate protein folding, stability and trafficking; meanwhile, the glycans of secreted proteins are important for secretion (Ray et al. 1998; Kadowaki et al. 2000; Cabral et al. 2001; Helenius and Aebi 2001; Rudd et al. 2001; Dwek et al. 2002; Simizu et al. 2004; Wujek et al. 2004) . For instance, Garrigue-Antar et al. (2002) demonstrated glycosylation sites in the CUB domains (complement component Clr/Cls, Uegf, and bone morphogenic protein 1) of BMP-1 are important for its secretion and stability. Although sequence analysis reveals six potential N-glycosylation sites on human BMP-2, five of which are located in the prosegment and one in the mature active region, whether or not these sites are actually occupied and essential for its function is unknown.
In this study, we found that N-glycosylation of human BMP-2 is essential for its secretion. Furthermore, we expressed Flag-tagged BMP-2 in CHO and human embryonic kidney 293T (HEK293T) cells and characterized the N-glycosylation sites of BMP-2. Site-directed mutation experiments revealed that human BMP-2 undergoes N-glycosylation on Asn135, Asn200 and Asn338. And N-glycosylation on Asn135 is important for its ER export toward the secretory pathway. Finally, we verified the conclusion and observed N-glycosylation of BMP-2 play a key role in osteoblast differentiation in MC3T3-E1 cells. Therefore, our results suggest that N-glycosylation of BMP-2 affects its induced osteoblast differentiation by regulating its secretory pathway.
Results N-linked glycosylation and initial N-linked glycan modification is required for efficient maturation and secretion of BMP-2 To determine whether glycosylation was necessary for BMP-2 secretion, we transiently expressed Flag-tagged human BMP-2 for 24 h in the CHO cells for 48 h in the presence of inhibitors of different stages of N-linked glycan (NLG) processing and analyzed the expression levels of BMP-2 by enzyme-linked immuno sorbent assay (ELISA) ( Figure 1A ). In the presence of tunicamycin (TM), which blocks the attachment of the precursor NLG chain to the nascent peptide, abolished secretion of BMP-2, and the amount of BMP-2 in the cell lysates, was also reduced ( Figure 1A ). Castanospermine (CST), a glucosidase inhibitor, which prevents initial glucose trimming and has been shown to inhibit glycan-dependent interaction with the ER lectin chaperones calnexin (CNX) and calreticulin (CRT; Jacob 1995). When BMP-2 was expressed in the presence of CST, secretion of BMP-2 was virtually abolished, and the amount retained in the cell lysates was also reduced ( Figure 1A ), suggesting that interaction with CNX and CRT is required to assist in the processing of BMP-2. BMP-2 was also expressed in the presence of swainsonine (SW) to inhibit the conversion of high mannose to complex glycans. And the SW had no effect on BMP-2 secretion, indicating that further processing of BMP-2 NLG chains in Golgi is not essential for its secretion ( Figure 1A ). Western blotting analysis showed that the N-glycosylation of BMP-2 in CHO cells was inhibited in the presence of TM, as the protein band was minished to 46 kDa ( Figure 1B ). In contrast, the immunoreactive band was surprisingly detected at 60 kDa in CST-treated cell lysates ( Figure 1B ). And the immunoreactive band of BMP-2 detected in SW-treated cell lysates was similar to wild-type BMP-2 (wtBMP-2) ( Figure 1B ). In keeping with the ELISA results, the secretion of exogenous BMP-2 was totally inhibited after TM treatment ( Figure 1B ). All these results suggest that N-glycosylation is required for the secretion of BMP-2.
However, it is known that the N-glycosylation status of a glycoprotein can differ between different cell lines (Kobata 1992; Schmieder et al. 2001; Vagin et al. 2008) . To test whether Fig. 1 . Effect of N-linked glycosylation inhibitors on BMP-2 expression and N-glycosylation of the BMP-2. (A) wtBMP-2 was transiently expressed in CHO cells in the presence of 1 μg/mLTM, 100 μg/mL CST or 10 μg/mL SW, and BMP-2 levels in the cell media or lysate analyzed by enzyme-linked immuno sorbent assay (ELISA) 2 days after transfection. Error bars represent mean ± SEM of three separate experiments each performed in duplicate. (B) The BMP-2 in media or lysate expressed in CHO cells with glycosylation inhibitors was determined by electrophoresis in 12% SDS-PAGE and then immunoblotted with anti-Flag antibodies. β-Actin was used as a loading control. All these data are representative of at least three independent experiments. N-glycosylation regulates BMP-2 function the N-glycosylation status of BMP-2 is dependent on cell types, we transiently expressed Flag-tagged BMP-2 in HEK293T cells and analyzed by immunoblotting. As shown in Supplementary data, Figure S1 , the immunoreactive bands in HEK293T cells were consistent with the previous observations in CHO cells ( Figure 1B) , suggesting that the N-glycosylation status of BMP-2 may independent of cell types and species. We, therefore, employed CHO cells mostly for subsequent experiments.
Construction of various BMP-2 mutants by the mutagenesis of potential N-glycosylation sites Although the N-glycosylation inhibition experiment confirmed the importance of N-glycosylation in human BMP-2 secretion, the contribution of individual N-glycosylated sites within the molecule could not be assessed. The primary aa sequence of human BMP-2 contains five potential N-linked glycosylation sites (Asn-Xaa-Ser/Thr) at the N135, N163, N164, N200 and N338 positions, four in the prosegment domain and one in the mature region, as shown in Figure 2 . To examine whether the five potential N-glycosylation sites are occupied by a glycosyl residue, we mutated the asparagine residues within the Asn-Xaa-Ser/Thr glycosylation consensus sequence in BMP-2 to glutamine residues (Figure 2 ). In addition to the five single mutants, we generated three double mutants (N135,200Q, N135,338Q and N200,338Q) and a triple mutant (N135,200, 338Q) for further research (Figure 2 ).
Identify the N-glycosylation sites of BMP-2 and detect the enzymatic activity of the N-glycosylation mutants As shown in Figure 2 , the primary amino acid sequence of human BMP-2 contains five potential N-linked glycosylation Fig. 2 . Schematic illustration of the potential N-glycosylation sites on the human BMP-2. Domain diagram of human BMP-2 and the sites corresponding to the putative N-glycosylation sites on the human BMP-2 (Asn135, Asn163, Asn164, Asn200 and Asn338) are shown by gray arrowheads. The crosses represent the removal of glycosylation at each N-glycan site by site-directed mutagenesis, i.e. Asn to Gln. sites. To ascertain which extensional carbohydrates contribute to the N-glycosylation of human BMP-2, we transiently overexpressed the five single mutants of BMP-2 in CHO cells. As shown in Figure 3A , the higher 60 kDa bands most likely represent fully glycosylated Flag-BMP-2, and the lower 46 kDa band represents the non-glycosylated control, which was expressed in Escherichia coli without its signal peptide. These results showed that wtBMP-2 and glycomutants at positions N135, N200 and N338 exhibited different electrophoretic mobilities ( Figure 3A) . However, there were no BMP-2 band shifts in the case of the N163Q and N164Q mutants ( Figure 3A) . To eliminate the possibility that a mutation on either consecutive N163Q or N164Q leads the N-glycosylation of the other site in a compensatory manner, we checked the electrophoretic mobilities but no band shifts between wtBMP-2 and the double mutant (N163,164Q; Supplementary data, Figure S2A ), which demonstrated that human BMP-2 is N-glycosylated at the predicted sites on N135, N200 and N338 as expected. In addition to the single mutants, the changes in molecular mass were observed for all double or triple mutants containing N135Q, N200Q and/or N338Q ( Figure 3A) . Furthermore, we also validated the mutation results in HEK293T cells ( Figure 3B ). The analysis of double mutants N135,163Q, N135,164Q, N163,200Q, N164,200Q, N163,338Q and N164, 338Q and the triple mutants N135,163,164Q, N163,164,200Q and N163,164,338Q confirmed our conclusion that human BMP-2 was N-glycosylated on N135, N200 and N338 (Supplementary data, Figure S2B ). This assumption was confirmed when we treated human BMP-2 with peptide:N-glycosidase F (PNGase F), an enzyme that cleaves between the innermost N-acetylglucosamine and asparagine residues of almost all N-glycan chains (Hayashi and Yamashita 2012) . As shown in Figure 4A , PNGase F markedly changed the electrophoretic behavior of BMP-2, which now migrated as a sharp band close to 46 kDa. To further demonstrate that the observed gel shift of the N135Q, N200Q and N338Q BMP-2 mutants was caused by the lack of N-glycosylation, we treated wtBMP-2 and all the mutants with PNGase F. After enzymatic deglycosylation, wtBMP-2 and mutants N163Q and N164Q co-migrated with mutants N135Q, N200Q and N338Q by immunoblotting ( Figure 4A ). And all mutants treated with PNGase F resulted in the characteristic shift of BMP-2 bands to the lower molecular mass ( Figure 4A ). Unexpectedly, PNGase F also had effect on the mobility of the triple mutant N135,200,338Q ( Figure 4A ), indicating that there might be other glycosylation sites except N135, N200 and N338. And the further work is in progress to look for the other potential glycosylation sites. To confirm these results using a different glycosidase, the cells transfected with Flag-BMP-2 were incubated with endoglycosidase H (Endo H), which cleaves between the two N-acetylglucosamine residues in the diacetylchitobiose core of the oligosaccharide, generating a truncated sugar molecule with one N-acetylglucosamine residue remaining on the asparagines (Bence and Sahin-Toth 2011) . Flag-tagged BMP-2 produced by this method was fully deglycosylated by Endo H. As seen with PNGase F, wt and all the mutants were Endo H sensitive exhibited faster mobility after Endo H treatment, during which the triple mutant N135,200, 338Q showed the fastest mobility ( Figure 4B ), which indicated that the N-glycans are required for the normal processing of human BMP-2. Together, these results were consistent with the fact that N135, N200 and N338 are N-glycosylation sites of human BMP-2, as shown in Figure 3 .
Specific NLG mutations affect expression and secretion of BMP-2
We have observed that N-glycosylation was essential for wtBMP-2 secretion ( Figure 1A ) and three of the potential Figure 5A ), indicating that N-glycosylation site N135 was necessary for BMP-2 secretion. Mutation of N135 virtually abolished secretion of BMP-2, the mature N135Q level was also reduced in the cell lysate compared with wtBMP-2 ( Figure 5B and C), indicating that the first N-linked glycosylation event in the ER after translocation is essential for BMP-2 processing and maturation. However, mutations of N200 and N338 affected neither the BMP-2 secretion ( Figure 5A ) nor the levels of its precursor form ( pro-BMP-2) in the cell lysate ( Figure 5B ). To confirm the ELISA results, we collected the media of the cells transfected with wtBMP-2 and all the N-glycosylation site mutants to provide a more detailed analysis of BMP-2 secretion. In accordance with previous reports, no Flag-tagged mature-BMP-2 (mat-BMP-2) were appeared in the media from the cells transfected with N135Q included mutants ( Figure 5C ). However, interestingly, the expression of pro-BMP-2 was markedly increased compared with wtBMP-2 within the cell lysate ( Figure 5C ), indicating intracellular retention but without accelerated degradation. To determine that the observed BMP-2 secretion effected by N135Q was due to loss of the glycan chain and not the aa mutation, we constructed further mutants by mutating the third aa in the glycosylation consensus sequence (Asn-Xaa-Ser/Thr) to alanine, thereby preserving the asparagine but preventing its glycosylation. Effect of S137A on BMP-2 secretion in CHO cells demonstrated similar to the N135Q mutation, with a reduction in the secretion of mutant S137A in the cell media (Supplementary data, Figure S3 ). This suggests that it is the loss of the N-glycan chain Fig. 5 . Effect of N-linked glycosylation mutation on the expression and secretion of BMP-2. BMP-2 NLG mutants were expressed in CHO cells and BMP-2 concentrations in the secreted media (A) and cell lysate (B) were analyzed by BMP-2 ELISA. Error bars represent the mean ± SEM of three separate experiments each performed in duplicate. (C) Cell lysate and media samples of wtBMP-2 and the BMP-2 glycosylation mutants were, respectively, analyzed by SDS-PAGE in 12 and 15% gels followed by western blotting with an anti-Flag antibody. β-Actin was used as a loading control. Pro-BMP-2 represents the precursor form of BMP-2, and mat-BMP-2 represents the mature form of BMP-2. All these data are representative of at least three independent experiments. Q Hang et al. that is responsible for the phenotype observed. All these results demonstrated that the N-glycosylation site of N135 was essential for the mat-BMP-2 formation and secretion.
To examine how this apparent secretion defect depends on the overall expression levels, we transfected CHO cells with increasing concentrations of expression plasmids for wtBMP-2 and mutant N135Q. Expression of BMP-2 in lysate and media increased proportionally with higher plasmid concentrations, as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis ( Figure 6A ) and the ability of secretion measurements ( Figure 6B ). In contrast, mutant N135Q exhibited major increments in the expression of BMP-2 in cell lysate but no expression of BMP-2 in the media over the same plasmid concentration range. And the secretion ability of the N135Q mutant exhibited no change with higher plasmid concentrations ( Figure 6A ). Accordingly, more dramatic differences in expression between wtBMP-2 and mutant N135Q were apparent at higher plasmid concentrations.
N135q mutant of BMP-2 was retained within the ER caused ER stress Because the N135Q mutant affected BMP-2 secretion and was retained within the cell, we investigated the intracellular fate of the mutant. The subcellular distributions of wt and glycosylation mutants of BMP-2 were examined using confocal laser scanning microscopy. As shown in Figure 7A , wtBMP-2, N200Q and N338Q mutants co-localized only partially with the ER marker CNX ( Figure 7A ). In contrast, the N135Q mutant largely co-localized with CNX, confirming their ER localization ( Figure 7A ). These data complete the N-glycan processing analysis, indicating that wtBMP-2, N200Q and N338Q mutants were partially processed to mature proteins and secreted from the ER, whereas the N135Q mutant impaired normal processing of the BMP-2 and was mainly retained within the ER. These results are consistent with the phenotype that N135Q exhibited no secretion ability.
The intracellular retention of the N135Q mutant suggested that the N135Q mutant might not fold properly resulting in ER stress. And previous studies had shown that a highly conserved unfolded protein response (UPR) signaling pathway was activated by ER stress in response to misfolded protein accumulation (Bertolotti et al. 2000) . If this is the case, markers of ER stress should be elevated in cells expressing the N135Q mutant. To test this hypothesis, we performed western blotting to detect the expression of ER stress markers. We found that the UPR was activated in N135Q mutants, as indicated by elevated levels of C/EBP homologous protein (CHOP, also known as GADD153), a transcription factor and the glucose-regulated protein 78 (GRP78, also known as Bip) that are activated at multiple levels during ER stress (Wang and Ron 1996; Marciniak et al. 2004 ; Figure 8A ). In addition, we used CRT, as another marker of ER stress. The results showed that the CRT expression level was also up-regulated in cells expressing the N135Q mutant ( Figure 8A ). In addition, we also measured mRNA levels of CRT and CHOP in cell lysates by reverse transcription-polymerase chain reaction (RT-PCR). We found that both of them were significantly up-regulated in cells expressing the N135Q mutant relative to cells transfected with wtBMP-2 ( Figure 8B ). The results demonstrated that the N135Q mutant was unable to fold properly and was retained within the CNX/ CRT cycle in CHO cells,
Mutation of BMP-2 NLG sites affecfts BMP2-induced osteoblast differentiation
Koh and colleagues demonstrated that BMP-2 could regulate osteoblast differentiation (Jang et al. 2012 ). Prior to determination of the effects of N-glycosylation on BMP-2 induced osteoblast differentiation. We first examined the N-glycosylation Fig. 6 . Effect of plasmid concentration on BMP-2 secretion from transfected CHO cells. Transfections were performed with increasing concentrations of empty Flag vector and wild type, N135Q expression plasmids of BMP-2 (from 50 to 2500 ng). Total plasmid DNA in the transfections was kept constant at 2500 ng by adding control vector. (A) Cell lysate and media samples of wtBMP-2 and the N135Q mutants were analyzed by 12% SDS-PAGE gels. β-Actin was used as a loading control. (B) The secretion ability of wild type and N135Q of BMP-2 was analyzed by BMP-2 ELISA in a concentration-dependent manner. Error bars represent the mean ± SEM of three separate experiments each performed in duplicate. All these data are representative of at least three independent experiments. N-glycosylation regulates BMP-2 function sites of BMP-2 in MC3T3-E1 cells. As shown in Supplementary data, Figure S4 , MC3T3-E1 cells were then transfected with wtBMP-2, N163Q, N164Q, N200Q and N338Q mutants and the cell lysates were analyzed by SDS-PAGE and BMP-2 secretion measurements. Consistent with our previous observation with CHO and HEK293T cells, BMP-2 in MC3T3-E1 cells was also N-glycosylated on N135, N200 and N338 sites (Supplementary data, Figure S4A ) and only the N135 site was essential for its secretion (Supplementary data, Figure S4B ).
We next investigated the effects of the N135Q mutant on osteoblastic differentiation, and we performed a time course experiment. MC3T3-E1 osteoblast cells were transfected with wtBMP-2 and N135Q mutant, respectively, on days 0, 2, 4 and 8 for measuring the ALP activity. As shown in Figure 9A , wtBMP-2 increased the ALP activity in a differentiation daydependent manner; however, the N135Q mutant did not affect the ALP activity of MC3T3-E1 cells during the indicated days compared with the control. And the ALP staining experiment confirmed the above results ( Figure 9B ). Furthermore, we also added recombinant wtBMP-2 in the culture of N135Q-transfected cells to examine the differentiation, and the differentiation ability of N135Q-transfected cells was significantly enhanced ( Figure 9B ). So far as we know, N135Q could induce ER stress and failed to induce osteoblast differentiation. Is there possibility that overexpression of the N135Q mutant could induce ER stress and attenuate the viability of osteoblast cells? To exclude this condition, we detected the effect of control, wtBMP-2 and N135Q mutant on the proliferation of osteoblast cells. As provided in Figure 9C , the N135Q mutant hardly affected the cell growth during osteoblast differentiation, indicating that N135Q failed to induce osteoblast differentiation is due to the fact that N-glycosylation site of N135 is essential for the formation and secretion of mat-BMP-2.
In addition, to confirm that the glycosylation site of N135 was sufficient to enhance BMP-2-mediated osteoblast differentiation. MC3T3-E1 cells were transfected with wtBMP-2 and N135Q mutant and total RNA was isolated, respectively, on days 0, 2, 4 and 8 for measuring gene expression profiles of osteogenic markers, such as ALP, OC and the transcription factor Runx2. As several lines of evidence suggested (Takuwa et al. 1991; Sakano et al. 1993; Ducy and Karsenty 1995; Chen et al. 1997; Saito et al. 2011 ), BMP-2 significantly increased the expression levels of ALP, OC and Runx2 in a differentiation day-dependent manner; however, the N135Q mutant did not induce osteoblast differentiation compared with the control groups in MC3T3-E1 cells ( Figure 9D ). Taken together, these findings indicated that the N135Q mutant of BMP-2 had no effect on osteoblastic differentiation in MC3T3-E1 cells, suggesting that glycosylation on N135 was necessary for osteoblastic differentiation in MC3T3-E1 cells.
Discussion
BMP-2 is one of the most important cytokines and plays several important roles in a variety of cellular functions ranging from embryogenesis, cell growth and osteoblast differentiation and the repair of bone fractures (Welch et al. 1998; Canalis et al. 2003) . Many members of BMPs undergo glycosylation, including BMP-1 and BMP-6 (Garrigue-Antar et al. Saremba et al. 2008) . And Israel et al. (1992) demonstrated that BMP-2 is a glycosylated protein, and the secreted BMP-2 contains high-mannose and complex N-linked oligosaccharides. However, the underlying biological functions of the glycosylated BMP-2 are yet to be delineated. In this study, we showed that BMP-2 is N-linked glycosylated at three sites within the molecule and that site N135 is important for its expression and secretion in CHO cells. We further validated the results in MC3T3-E1 cells and showed that the N135 site is essential for BMP-2-induced osteoblast differentiation. Taken together, our data as summarized here provide novel evidence that N-linked glycosylation of BMP-2 is involved in its expression, secretion and its ability to induce osteoblast differentiation. It is well accepted that glycosylation plays a pivotal role in the function of a glycoprotein (Parodi 2000; Helenius and Aebi 2001) , and N-linked glycosylation is a common post-translational modification during the maturation and secretion processes of many proteins (Kadowaki et al. 2000; Garrigue-Antar et al. 2002; Zhou et al. 2004) , which also plays important roles in cell-cell recognition, signaling and other cellular processes (Freeze 2006; Ohtsubo and Marth 2006) , and the positions glycosylated in a glycoprotein appear conserved (Freeze 2006) . Chungoo et al. confirmed that the conservation of glycosylated asparagines is accompanied by the conservation of the canonical motif sequence for glycosylation, suggesting that glycosylation is very important in the species evolution (Park and Zhang 2011) .
Herein, using specific chemical inhibitors, we demonstrated that blocking the addition of NLG with TM abolished secretion of BMP-2, while blocking the conversion from high mannose to complex structures with SW had no effect on either expression or secretion. Significantly, CST treatment also abolished BMP-2 secretion, suggesting that the interaction of BMP-2 with the lectin like chaperones CNX and/or CRT is required for effective BMP-2 processing. Therefore, we can get the conclusion that N-glycans are important for the secretion of BMP-2.
It is estimated that 90% proteins with the sequence Asn-X-Ser/Thr are glycosylated (Gavel and von Heijne 1990) . Although the human BMP-2 sequences contain five potential N-linked glycosylation sites (three occur within the protein prosegment domain and one in the mature region), whether or not these sites are actually occupied is unknown. Our data here showed that only three sites of the consensus Asn-X-Ser/Thr sites of BMP-2 were glycosylated (N135, N200 and N338). Furthermore, Israel et al. (1992) reported that mat-BMP-2 was sensitive to PNGase F and Endo H, and our results showed that the N-glycans of BMP-2 glycoproteins were entirely PNGase F and Endo H sensitive, indicating that BMP-2 N-glycosylation sites were occupied with high-mannose or complex-type glycans. Our next question was to identify which one(s) of these glycosylated sites had a role in secretion. And N-glycosylation of N135 was confirmed as potential crucial process for the secretory protein. However, BMP-2 without the glycosylation on N200 and N338 were still secreted into the medium efficiency. Similar results were obtained when we abolished the N-linked glycosylation site by mutating the serine or threonine residue to alanine in the Asn-X-Ser/Thr sequence at sites S137, S202 and T340, confirming that the secretion defects were due to the loss of the NLG chain.
It has been reported that glycoproteins are most sensitive to the removal of glycosylation sites near their N termini, as these sites first engage the protein folding machinery in the ER to initiate the correct folding process (Doms et al. 1985; Hebert et al. 1997; Helenius and Aebi 2001) . In this study, the extent of the secretion defect of the N135Q mutant was proportional to the expression levels, suggesting that this mutant is poorly folded in the secretory pathway. Consistent with this interpretation, confocal microscopy confirmed that the N135Q mutant were predominantly retained within the ER, but not N200Q and N338Q mutants, indicating that lack of glycan at N200 or N338 is not sufficient to affect folding and targeting or that it can be compensated by the neighboring oligosaccharide chains.
Our results suggested that initial N-glycans on N135 play vital roles in the quality control of BMP-2 in the ER. The possible explanation might be: N135 located in a specific domain of the protein, which interfering the protein folding; or the N135Q disrupt the interactin between BMP-2 and partner proteins that assist protein folding. N-linked glycosylation occurs Fig. 8 . ER stress markers in CHO cells expressing wtBMP-2 and N135Q mutant. (A) Cells expressing wt, N135Q, N200Q and N338Q mutants of BMP-2 were analyzed by western blotting to determine the levels of the pro-BMP-2, CRT and the pro-apoptotic ER stress indicator protein CHOP. β-Actin was used as a loading control. (B) mRNA levels of CRT and CHOP in wtBMP-2 or N135Q mutant transfected CHO cells were measured by real-time PCR as described in Experimental procedures. GAPDH was measured as a control for sample integrity and equal loading. Error bars represent the mean ± SEM of three separate experiments each performed in duplicate. All these data are representative of at least three independent experiments. N-glycosylation regulates BMP-2 function cotranslationally as the nascent peptide chain is translocated into the ER and it has been demonstrated that the location of the initial NLG site determines which chaperone proteins interact with. Previous reports showed that if the first glycosyl residue is located within 50 aa, interaction is normally with CNX/CRT. It is well known that the interaction of glycoproteins with the lectin chaperones from the ER, CNX or CRT is required for their correct folding (Morais et al. 2003; Helenius and Aebi 2004) . However, if the glycan is after the first 50 aa, the protein normally interacts with Bip first, before further interaction with CNX and CRT (Molinari and Helenius 2000) . Therefore, the prevention of glycosylation at N135 may therefore alter the ability of BMP-2 to interact with the correct chaperone pathway and result in misfolding of the newly forming peptide. If glycoproteins fail to attain the correct fold, they can either be accumulated in the ER as aggregates, be translocated to the cytosolic face of the ER and be degraded by the proteasome or they can be transported to the Golgi apparatus and divert to the lysosome where they are degraded (Ruusala et al. 1992; Tsukuba and Bond 1998; Kadowaki et al. 2000; Trombetta and Parodi 2003; Helenius and Aebi 2004 ). The elevated level of the chaperone protein Bip, CRT and the proapoptotic indicator protein CHOP after the N135Q mutation have confirmed the induction of UPR and ER stress in response to the accumulation of misfolded BMP-2 in CHO cells. These observations indicate that N-glycosylation at N135 is required for efficient folding of human BMP-2.
In view of this phenomenon, one possible explanation might be: BMP-2 would fail to attain its final conformation and would be retained in the ER in the absence of this folding step. Fig. 9 . Effects of wtBMP-2 and N135Q mutant on the differentiation and osteogenic gene expression profile of MC3T3-E1 cells. MC3T3-E1 cells transfected with wtBMP-2 and N135Q mutant were cultured in differentiation medium for 0, 2, 4 and 8 days, respectively. Fresh medium was changed twice per week. (A) After differentiation, ALP activity were analyzed on the indicated number of days and measured as fold increase based on normal control with means (n = 3) ± SE. (B) The ALP staining of the indicated that MC3T3-E1 cells on indicated number of days were observed by phase-contrast microscopy were performed (×40). (C) Cell growth was examined by Cell Counting Kit-8 assay at the indicated time. (D) MC3T3-E1 cells were transfected with wtBMP-2 and N135Q mutant. Total RNAwas isolated, respectively, after indicated days of differentiation. mRNA levels of OC, ALP and Runx2 were measured by real-time PCR. Real-time PCR values are normalized to GAPDH. These data were means ± SEM. *P < 0.05, **P < 0.01,compared with the control group. All these data are representative of at least three independent experiments. Scale bars, 100 μm.
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As a consequence, the protein would remain as an inactive precursor protein not only because of impaired folding and heterodimerization but also because further proteolytic processing to the mature form, which takes place in the Golgi, would not occur due to compartmentalization constraints. In agreement, the mature form of the N135Q mutant was absent both in the media and in cell lysate. Nevertheless, certain N-glycan chains had a significant detrimental effect on heterodimerization and proteolytic processing, but whether this is a consequence of protein misfolding due to a lack of glycan chains or a direct influence on heterodimer formation requires further study. Taken together, the data will be helpful to the understanding of why the mutant of N135Q could bot secrete to the extracellular.
Previous studies have shown that BMP-2 potentially promote the osteogenic differentiation Mahoney et al. 2008; Jang et al. 2012) . And Davis et al. (2011) and Chen et al. (2012) demonstrated that BMP-2 protein regulates osteogenic differentiation via ALP, OC and runt-related transcription factor-2 (RUNX2). Our data tend to suggest that BMP-2 was glycosylated on N135, N200 and N338, and site N135 was essential for BMP-2 secretion in MC3T3-E1 cells and therefore abolished the BMP-2-mediated osteogenic differentiation; however, the differentiation ability of N135Q-transfected cells were significantly enhanced by adding recombinant wtBMP-2, expounding the importance of N-linked glycosylation for BMP-2-induced osteogenic differentiation.
In summary, our results provide evidences of the critical role that individual NLG play in determining BMP-2 secretion and function. Remarkably, we identified three N-linked glycosylation sites in BMP-2. And we postulate that N135 is essential for its expression and secretion because, as the first NLG site, it directs the nascent polypeptide to the appropriate chaperones, and without which the BMP-2 cannot leave the ER, resulting the ER stress. In addition, we demonstrated that glycosylation at N135 is necessary for BMP-2-induced osteogenic differentiation. Taken together, these data will be helpful to the understanding of glycosylation in the secretion and function of BMP-2, which may provide evidence for importance of N-glycosylation site conservation.
Materials and methods

Reagents and antibodies
The BMP-2 ELISA kit, which tests the mat-BMP-2, and recombinant wtBMP-2 were obtained from R&D Systems (Minneapolis, MN). The ALP assay buffer and ALP staining kit were purchased from Sigma. The TM, CST and SW used in this study were purchased from Sigma. And the antibodies used in this study include: rabbit polyclonal anti-CNX antibody, mouse monoclonal anti-CHOP antibody and mouse polyclonal anti-β-actin antibody (Santa Cruz), rabbit polyclonal anti-CRT antibody (Abcam) and mouse monoclonal anti-Flag antibody (Sigma).
Cell culture CHO, HEK293T and mouse osteoblastic cell line MC3T3-E1 cells were purchased from Chinese Academy of Sciences Cell Library (Shanghai, China). CHO cells and HEK293T cells were grown in Dulbecco's modified Eagle media and F12K (Gibco) containing 10% fetal bovine serum (FBS; Gibco), 4 mM glutamine and 1% penicillin/streptomycin (Invitrogen) at 37°C in a humidified atmosphere containing 5% CO 2 , respectively. MC3T3-E1 cells were cultured in α-minimum essential medium (α-MEM) (Gibco) with 10% FBS and 1% penicillin/ streptomycin at 37°C. To induce differentiation, cells were seeded onto a 6-, 12-or 96-well culture dish and allowed to grow to confluence. At confluence (day 0), cells were transferred to α-MEM containing 10% FBS, 1% penicillin/streptomycin, 10 mM β-glycerophosphate and 100 μg/mL ascorbic acid and induced to differentiation for the indicated days.
Plasmid construction, site-directed mutagenesis and transfection The coding DNA for human BMP-2 was PCR amplified from total complementary DNA (cDNA) prepared from HEK293T cells using the following primers: human BMP-2 EcoRI sense, 5′-CGGAATTCAATGGTGGCCGGGAC-3′ (where the EcoRI site is underlined) and human BMP-2 BamHI antisense, 5′-CGGGATCCGCGACACCCACAACCCT-3′ (where the BamHI site is underlined). The PCR product was digested with EcoRI and BamHI and subcloned into the C-terminal p3 × FLAG-CMV vector. To construct the N-glycosylation site mutants of BMP-2, one (for single mutation) or two (for double or triple mutations) of the asparagine(N) residues at the potential sites were replaced with glutamine(Q) by overlap extension PCR mutagenesis and ligated into the C-terminal p3 × FLAG-CMV expression plasmid and the oligonucleotides used in site mutant vector constructions were shown in Supplementary data, Table S1 . All mutants were verified by sequence analysis. And the transient transfections were performed using lipofectamine 2000 (Invitrogen) following the manufacturer's recommendation.
Inhibition of glycosylation
To completely inhibit N-linked glycosylation, CHO cells or HEK293T cells were cultured for 48 h in the medium containing 1 μg/mLTM, 100 μg/mL CST or 10 μg/mL SW.
Deglycosylation
The isolated intact cells were treated with 1000 U/mL PNGase F or 1000 U/mL Endo H at 37°C for 3 h following the manufacturer's instructions or left untreated. Samples were then dissolved in 2 × SDS loading buffer (20 mM Tris-HCl, pH 8.0, 100 mM dithiothreitol, 2% SDS, 20% glycerol, 0.016% Bromophenol blue) and separated by SDS-PAGE.
Cell fractionation and immunoblot analysis
Cell protein was promptly homogenized in a homogenization buffer containing 1 M Tris-HCl ( pH 7.5), 1% Triton X-100, 1% NP-40 (nonidet p-40), 10% SDS, 0.5% sodium deoxycholate, 0.5 M ethylene diamine tetraacetic acid, 10 μg/mL leupeptin, 10 μg/mL aprotinin and 1 mM phenylmethanesulfonyl fluoride (PMSF), then centrifuged at 10,000 × g for 30 min to collect the supernatant. Protein concentrations were determined by the Bio-Rad protein assay (Bio-Rad, Hercules, CA), and BMP-2 was quantified in conditioned medium after precipitation in 10% trichloroacetic acid, washing of the pellet with N-glycosylation regulates BMP-2 function acetone and solubilization in SDS sample buffer. And the proteins were separated with SDS-PAGE and analyzed by immunoblotting as reported previously (Hang et al. 2012) .
Immunofluorescence CHO cells were transfected with indicated plasmids for 48 h. After treatment, the cells were fixed with 8% paraformaldehyde (1 h), permeabilized with 0.1% Triton X-100 (15 min) and blocked for non-specific binding in phosphate-buffered saline (PBS), 1% albumin from bovine serum (BSA) for 2 h. Cells were, respectively, stained with mouse anti-Flag monoclonal antibody or rabbit anti-CNX polyclonal antibody at 4°C overnight. After washing in PBS three times for 10 min each, the secondary antibodies (CY3-Donkey-anti-Rabbit or FITCDonkey-anti-Mouse, 1:500 dilution, Jackson Laboratory) were added in the dark room and incubated for 2-3 h at room temperature. Images were acquired using a Leica-confocal microscope (Germany). For quantification, a minimum of 400 cells were counted for each determination, and results were derived from at least three independent experiments.
ELISA assay Cells were treated with N-glycosylation inhibitors or transfected with indicated plasmids for 48 h. After treatment, the medium was diluted twice and then stored at −80°C until assay. BMP-2 in the medium was assayed using the BMP-2 enzyme immunoassay kits (R&D Systems), according to the procedure described by the manufacturer.
ALP activity and staining
The ALP activity in the cells was assayed after transfected with indicated plasmids for 48 h or added the wtBMP-2 and then induced to differentiation for 0, 2, 4 and 8 days. Briefly, ALP reagents were added to the different subset wells and then incubated at 37°C for 2 h at indicated days. The absorbance was quantified using an automated plate reader at a test wavelength of 450 nm at different times and then translated into ALP activity value. And the ALP staining was performed according to their procedure described by the manufacturer.
Cell proliferation assay
To evaluate the effect of transfection of the N135Q mutant, cells were seeded on a 96-well cell culture cluster (Corning Inc., Corning, NY) at a concentration of 2 × 10 3 /well in a volumes of 100 μL and grew overnight and transfected with indicated plasmids for 48 h and then induced to differentiation for 0, 2, 4 and 8 days. Cell Counting Kit-8 reagents (Dojindo, Kumamoto, Japan) were added to the different subset wells and then incubated at 37°C at indicated days. The absorbance was quantified using an automated plate reader at a test wavelength of 450 nm at different times.
RT-PCR and quantitative real-time PCR For RT-PCR, total RNA was isolated from the indicated CHO cells using TRIzol (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized using the Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany). RT-PCR was performed using a PCR Master Mix (Promega) and an appropriate pair of primers. The RT-PCR sequences of the specific primers pairs for CRT, CHOP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were shown in Supplementary data, Table S2 . Cycling parameters were: 94°C for 45 s, 55°C for 45 s, 72°C for 30 s and total 30 cycles. The GAPDH was used as an internal control. All the PCR products were separated by agarose gel electrophoresis and stained with ethidium bromide. To determine ALP, OC, Type I and Runx2 mRNA expression, total RNA was isolated from the indicated MC3T3-E1 cells using TRIzol (Invitrogen) according to the manufacturer's instructions. Each mRNA was measured using a quantitative real-time PCR assay, which employed LightCycler ® TaqMan ® Master (Roche Diagnostics), a Universal ProbeLibrary Probe (UPL Probe; Roche Diagnostics), an appropriate pair of primers according to the manufacturer's protocol. The sequences of specific primers and UPL Probes used are shown in Supplementary data, Table S3 . Expression values were normalized to GAPDH.
Statistics analysis
All experiments were repeated at least three times. All numerical data were described as the mean ± SEM. Data were analyzed using the two-tailed t-test. A probability value of 0.05 or less was considered significant.
Supplementary data
Supplementary data for this article is available online at http:// glycob.oxfordjournals.org/.
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